Square Enix showed off its new gacha game, Dissidia Duellum Final Fantasy, which is set for a 2026 release and a closed Android beta test in November. It’s a three-versus-three game, where you’ll need ...

Square Enix just dropped a bombshell tease for Final Fantasy fans craving more crossover chaos: The beloved Dissidia Final Fantasy series is staging a comeback as a brand-new mobile-exclusive “Team ...

DISSIDIA DUELLUM FINAL FANTASY coming to iOS/Android 2026 The latest entry in the DISSIDIA series A new DISSIDIA story unfolds in modern Tokyo, where legendary FINAL FANTASY warriors assemble to save ...

Scott Baird is a contributor with over a decade's experience writing about video games, along with board games and tabletop RPGs. Scott has previously worked for Dexerto, Cracked, Dorkly, and Gamepur.

Check out the Announcement Trailer for Dissidia Duellum Final Fantasy, a new mobile installment in the Dissidia series developed by NHN PlayArt and Square Enix. Legendary heroes from across Final ...

A giant crystal appears in the city of Tokyo. The blue-glowing crystal blended into daily life and became a familiar presence. However, those peaceful times came to a sudden end. Strange monsters ...

Final Fantasy is a lot like Mario in that it’s one of the only series out there with so many iconic characters that you can basically fill an entire crossover game with Final Fantasy characters alone.

Square Enix and NHN PlayArt have announced free-to-play three-versus-three team boss battle arena game, Dissidia Duellum Final Fantasy, for iOS and Android. It will launch in 2026. Modern-day Tokyo is ...

A new Dissidia Final Fantasy game is on the way. Dissidia Final Fantasy brings together the largest collection of Final Fantasy characters ever in a fighting game where players can choose their ...

Gilgamesh Brewing started in 2009 by three brothers and their father in Turner. They opened their first restaurant and pub in 2012 in southeast Salem. From 2019 to 2024, they opened three more ...

AbbVie (NYSE:ABBV) has agreed to acquire from Gilgamesh Pharmaceuticals its lead investigational candidate, Bretisilocin, for up to $1.2 billion. The deal includes upfront payment plus development ...